ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3222

Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

Peter C. Taylor1, Michael Schiff2, Qingmin Wang3, Yusang Jiang3, Regina Kurrasch4, Shruti Daga5, Ravi Rao6, Benjamin Hsu3 and Paul-Peter Tak7, 1Kennedy Institute of Rheumatology, NDORMs, University of Oxford, Oxford, United Kingdom, 2University of Colorado, School of Medicine, Denver, CO, 3Janssen Research & Development, LLC, Spring House, PA, 4GlaxoSmithKline, Collegeville, PA, 5GlaxoSmithKline, Uxbridge, United Kingdom, 6GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, 7GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic drugs, IL-6, monoclonal antibodies and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: New Biologics and Remission Induction

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Sirukumab, a human monoclonal antibody that selectively binds to the cytokine IL-6 with high affinity, is under development for rheumatoid arthritis (RA) and other diseases.  The objective of this study was to compare the efficacy and safety of sirukumab monotherapy and adalimumab monotherapy in biologic-naive patients (pts) with active RA.  

Methods: In this Phase 3 global study (SIRROUND-H), 559 biologic-naive pts with active RA who were intolerant to methotrexate (MTX), considered inappropriate for MTX treatment for safety reasons, or were inadequate responders to MTX were randomized (1:1:1) to sirukumab SC 50mg q4w, sirukumab SC 100mg q2w, or adalimumab SC 40mg q2w, stratified by the reason for MTX failure.  Pts with <20% improvement in swollen and tender joint counts at Wk 16 qualified for early escape (adalimumab to q1w dosing; sirukumab 50mg q4w to 100mg q2w).  Co-primary endpoints were change from baseline in DAS28 (ESR) at Wk 24 and proportion of pts achieving ACR50 at Wk 24.  The treatment comparison of interest for the primary hypotheses was sirukumab 100mg q2w vs adalimumab 40mg q2w.  If the first or both of the primary hypotheses were met, the study would be considered positive.  

Results: A significantly greater improvement in DAS28 (ESR) at Wk 24 was demonstrated with sirukumab 100mg q2w (P <0.001) and sirukumab 50mg q4w (P = 0.013) vs adalimumab 40mg q2w (Table).  All 3 treatment groups showed clinically relevant improvements in ACR50 response at Wk 24, but differences between sirukumab and adalimumab were not statistically significant (ie, hypotheses for the second co-primary endpoint were not met).  A clinically relevant proportion of pts attained the major secondary endpoints of DAS28 (ESR) remission and ACR20 response at Wk 24 in all 3 treatment groups.  Numerical differences were observed in efficacy endpoints depending on the reason pts failed MTX (Table).  Changes from baseline in CDAI, SDAI, HAQ-DI, SF-36 and FACIT-Fatigue were clinically important for all 3 treatment groups at Wk 24.  Efficacy was observed with both sirukumab doses as monotherapy from as early as Wk 2 for most endpoints and sustained through Wk 24.  A greater proportion of pts had ≥1 AE through Wk 24 with sirukumab 100mg q2w (63.6%) vs sirukumab 50mg q4w (57.0%) and adalimumab 40mg q2w (55.4%), and rates of serious AEs were 2.7%, 7.0%, and 4.3%, respectively; no deaths were reported through Wk 24.  

Conclusion: In biologic-naive pts with active RA who were intolerant to, considered inappropriate for treatment with, or inadequate responders to MTX, sirukumab monotherapy SC 50mg q4w and 100mg q2w reduced signs/symptoms of RA.  Significantly greater improvements in DAS28 (ESR) at Wk 24 were demonstrated with both doses of sirukumab monotherapy vs adalimumab monotherapy, while ACR responses were similar.  The safety profile of sirukumab was similar to the known safety profile of anti-IL-6 receptor biologics.  


Disclosure: P. C. Taylor, GSK, UCB, JANSSEN, 2,JANSSEN, UCB, PFIZER, ABBVIE, LILLY, BMS, ROCHE, GSK, NOVARTIS, SANDOZ, BIOGEN, BAXALTA, SANOFI, 5; M. Schiff, J&J; Abbvie, 5,Abbvie, 8; Q. Wang, Janssen Research and Development, LLC, 3,Janssen Research and Development, LLC, 1; Y. Jiang, Janssen Research & Development, LLC, 9; R. Kurrasch, GlaxoSmithKline, 3,GlaxoSmithKline, 1; S. Daga, GlaxoSmithKline, 1,GlaxoSmithKline, 3; R. Rao, GlaxoSmithKline, 3,GlaxoSmithKline, 1; B. Hsu, Janssen Research & Development, LLC, 1,Janssen Research & Development, LLC, 3; P. P. Tak, GlaxoSmithKline, 1,GlaxoSmithKline, 3.

To cite this abstract in AMA style:

Taylor PC, Schiff M, Wang Q, Jiang Y, Kurrasch R, Daga S, Rao R, Hsu B, Tak PP. Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-monotherapy-with-sirukumab-an-anti-il-6-cytokine-monoclonal-antibody-compared-with-adalimumab-monotherapy-in-biologic-naive-patients-with-active-rheumatoid-arthritis/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-monotherapy-with-sirukumab-an-anti-il-6-cytokine-monoclonal-antibody-compared-with-adalimumab-monotherapy-in-biologic-naive-patients-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences